Magainin 2
Overview
Magainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells. Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens.
Key Research Findings
Early preclinical studies demonstrated activity against gram-positive and gram-negative bacteria, fungi, and protozoa in vitro and in animal infection models. Clinical development of magainin 2 itself was limited due to modest potency and susceptibility to proteolytic degradation. Derivatives such as pexiganan were subsequently developed to improve stability and therapeutic potential.
Topical
Research Phase
Interested in Magainin 2?
Find a verified provider experienced with Magainin 2 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Magainin 2 ProviderRelated Peptides
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fusion step. Enfuvirtide binds to the first heptad repeat (HR1) region of gp41, preventing the conformational change required for viral-cell membrane fusion. It is the first and only FDA-approved fusion inhibitor and is active against HIV-1 strains resistant to other antiretroviral drug classes.
Pexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic stability. It disrupts bacterial membranes through electrostatic interaction and pore formation, demonstrating broad-spectrum activity against gram-positive and gram-negative organisms, including methicillin-resistant Staphylococcus aureus. Pexiganan was developed as a topical agent for infected diabetic foot ulcers, leveraging its rapid bactericidal action and low resistance potential. Structural modifications from the parent magainin sequence improve its pharmacological profile for clinical use.
Omiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses. Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices.
Iseganan (IB-367)
InvestigationalIseganan is a 17-amino acid synthetic analog of protegrin, a naturally occurring antimicrobial peptide found in porcine leukocytes. It disrupts microbial cell membranes via a beta-sheet structure stabilized by disulfide bonds, conferring broad-spectrum activity against bacteria, fungi, and some viruses. Iseganan was developed primarily as an oral rinse to prevent ventilator-associated pneumonia and oral mucositis in immunocompromised patients. Its rapid microbicidal action and low systemic absorption profile supported its formulation for topical oral use.